Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)

Nicholas Giustini, Lyudmila Bazhenova UCSD Moores Cancer Center, Department of Hematology and Oncology, 3855 Health Sciences Drive MC #0987, La Jolla, CA, 92093-0829, USACorrespondence: Nicholas Giustini 3855 Health Sciences Drive #0829, La Jolla, CA, 92093-0829 Email ngiustini@health.ucsd.eduAbstra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giustini N, Bazhenova L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	nsclc immunotherapy biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d1a3a4b3ebf44cf6bfd02cde9b7868d4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d1a3a4b3ebf44cf6bfd02cde9b7868d4
record_format	dspace
spelling	oai:doaj.org-article:d1a3a4b3ebf44cf6bfd02cde9b7868d42021-12-02T14:02:58ZRecognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)1179-2728https://doaj.org/article/d1a3a4b3ebf44cf6bfd02cde9b7868d42021-03-01T00:00:00Zhttps://www.dovepress.com/recognizing-prognostic-and-predictive-biomarkers-in-the-treatment-of-n-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Nicholas Giustini, Lyudmila Bazhenova UCSD Moores Cancer Center, Department of Hematology and Oncology, 3855 Health Sciences Drive MC #0987, La Jolla, CA, 92093-0829, USACorrespondence: Nicholas Giustini 3855 Health Sciences Drive #0829, La Jolla, CA, 92093-0829 Email ngiustini@health.ucsd.eduAbstract: Immunotherapy plays a central role in the treatment of NSCLC and biomarkers predicting response to ICIs are valuable therapeutic tools. Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is integral in therapy selection as its positive predictive nature to ICIs in the metastatic setting is well documented. Tumor mutational burden (TMB) has undergone much study and, while results are somewhat mixed, there is evidence for its positive predictive value with ICI use. Additional markers such as tumor-infiltrating lymphocytes (TILs), gene expression profiling (GEP), mismatch repair (MMR) and microsatellite instability (MSI), somatic mutations, neutrophil to leukocyte ratio (NLR), smoking history, medication history, and immune-related adverse event (irAE) development can further guide clinicians.Keywords: NSCLC, immunotherapy, biomarkersGiustini NBazhenova LDove Medical PressarticlensclcimmunotherapybiomarkersNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 12, Pp 21-34 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nsclc immunotherapy biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	nsclc immunotherapy biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Giustini N Bazhenova L Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
description	Nicholas Giustini, Lyudmila Bazhenova UCSD Moores Cancer Center, Department of Hematology and Oncology, 3855 Health Sciences Drive MC #0987, La Jolla, CA, 92093-0829, USACorrespondence: Nicholas Giustini 3855 Health Sciences Drive #0829, La Jolla, CA, 92093-0829 Email ngiustini@health.ucsd.eduAbstract: Immunotherapy plays a central role in the treatment of NSCLC and biomarkers predicting response to ICIs are valuable therapeutic tools. Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is integral in therapy selection as its positive predictive nature to ICIs in the metastatic setting is well documented. Tumor mutational burden (TMB) has undergone much study and, while results are somewhat mixed, there is evidence for its positive predictive value with ICI use. Additional markers such as tumor-infiltrating lymphocytes (TILs), gene expression profiling (GEP), mismatch repair (MMR) and microsatellite instability (MSI), somatic mutations, neutrophil to leukocyte ratio (NLR), smoking history, medication history, and immune-related adverse event (irAE) development can further guide clinicians.Keywords: NSCLC, immunotherapy, biomarkers
format	article
author	Giustini N Bazhenova L
author_facet	Giustini N Bazhenova L
author_sort	Giustini N
title	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
title_short	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
title_full	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
title_fullStr	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
title_full_unstemmed	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
title_sort	recognizing prognostic and predictive biomarkers in the treatment of non-small cell lung cancer (nsclc) with immune checkpoint inhibitors (icis)
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/d1a3a4b3ebf44cf6bfd02cde9b7868d4
work_keys_str_mv	AT giustinin recognizingprognosticandpredictivebiomarkersinthetreatmentofnonsmallcelllungcancernsclcwithimmunecheckpointinhibitorsicis AT bazhenoval recognizingprognosticandpredictivebiomarkersinthetreatmentofnonsmallcelllungcancernsclcwithimmunecheckpointinhibitorsicis
_version_	1718392110513651712

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)

Ejemplares similares